Getting to the heart of COX-2 inhibition
1Vanderbilt University Medical School, Division of Nephrology, Nashville, TN 37232, USA.
Cell Metabolism
|September 13, 2005
Insights
Aspirin benefits heart health, but COX-2 inhibitors may harm it. New research reveals how two prostaglandin receptors mediate these opposing cardiovascular effects, clarifying aspirin and COX-2 inhibitor impacts.
Area of Science:
- Cardiovascular Science
- Pharmacology
- Molecular Biology
Background:
- Aspirin is known for cardioprotective effects, while cyclooxygenase-2 (COX-2) inhibitors have been linked to adverse cardiovascular events.
- The differential cardiovascular impact of aspirin and COX-2 inhibitors suggests distinct molecular mechanisms.
- Prostaglandins play a crucial role in cardiovascular homeostasis and inflammation.
Discussion:
- This study investigates the roles of two specific prostaglandin receptors in mediating the cardiovascular effects of aspirin and COX-2 inhibitors.
- Understanding these receptor pathways is key to explaining the conflicting cardiovascular outcomes observed with these drug classes.
- The research highlights the complexity of prostaglandin signaling in cardiovascular health and disease.
Key Insights:
- Two distinct prostaglandin receptors differentially mediate the cardiovascular effects of aspirin and COX-2 inhibitors.
- Aspirin's cardioprotective action and COX-2 inhibitors' potential cardiac injury are linked to these specific receptor pathways.
- This clarifies the molecular basis for opposing cardiovascular effects observed with these commonly used drugs.
Outlook:
- Further research into these prostaglandin receptors could lead to the development of safer anti-inflammatory drugs with improved cardiovascular safety profiles.
- Targeting specific prostaglandin receptors may offer novel therapeutic strategies for cardiovascular disease prevention and treatment.
- These findings pave the way for personalized medicine approaches in managing cardiovascular risk associated with NSAID use.
Abstract:
Aspirin protects against heart disease, while COX-2 Inhibitors appear to injure the heart. The studies by [this Issue of Cell Metabolism]) shed light on two distinct prostaglandin receptors contributing to these conflicting cardiovascular effects.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:30Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...